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A B S T R A C T
Vitamin D has a positive impact on our overall health. Also there are a few conditions with strong evidence for a pro-
tective effect of vitamin D, such as bone diseases, internal cancers, multiple sclerosis, hypertension and DM type 1. Skin
is the major source of vitamin D through the action of UVB light on keratinocytes, although the biologically active form
of vitamin D is not exclusively produced in the kidney, but also in prostate, colon, skin and osteoblast where it acts as an
autocrine or paracrine hormone. In the past decade raising incidence of skin cancers, especially melanoma and its con-
nection with sun exposure lead to a sun protection policies and practices as part of the public health campaigns. The
question is how much solar UV exposure is adequate to maintain the balance between the risk and the benefit. We as der-
matologists have to raise public awareness of the potential health effects from excessive exposure to UV radiation but also
we have to be aware that adequate blood level of vitamin D is necessary for optimal health. So future recommendation on
sun protection have to balance between the risk and benefits of sun exposure, as well as to promote vitamin D supple-
mentation as a safe alternatives in high risk population.
Key words: vitamin D, UVB, sun protection policies, vitamin D supplementation
History of Vitamin D
Vitamin D has been discovered 80 years ago, but first
evidence of vitamin D deficiency occurred during the sev-
enteenth century in the northern Europe with the indus-
trial revolution. In the crowded, big cities polluted by the
pall due to the burning of coal children by the age of 2 de-
veloped severe growth retardation and deformities of the
skeleton that persisted throughout the afflicted life1. In
1822 Sniadecki recognized the association between the
lack of sunlight in the Warsaw and the rickets, but it was
not until 1919 that Huldschinsky reported successful
cure of rickets within 3 months after exposure to ultravi-
olet radiation from a mercury arc lamp. The connection
between the exposure to sunlight or artificial UV radia-
tion and the cure of the rickets led to the concept of irra-
diating various foods. Steenbock first recommended irra-
diation of milk fortified with provitamin D. Vitamin D
fortification in 1930s eradicated rickets as a significant
health problem. Today in United States milk, some cere-
als and bread are still fortified while in Europe milk is
not fortified but instead are margarine, some cereals and
bread.
Biology of Vitamin D
Vitamin D is fat soluble vitamin that exists in two
forms, as cholecalciferol (vitamin D3) and ergosterol (vi-
tamin D2). Vitamin D3 is naturally occurring form from
animal food, while vitamin D2 is produced in plants, pri-
marily yeast when exposed to ultraviolet B radiation
(UV-B). The main source of vitamin D is the endogenous
production of vitamin D3 in human skin through the ac-
tion of ultraviolet B (UV-B) radiation. Normally 90% of
the body’s needs in vitamin D has to be produced in the
skin because with the exception of some kind of fatty
fishes (herring, salmon, mackerel, sardine, etc.) other
foods contains only limited amounts of vitamin D2. The
photosynthesis of vitamin D3 occur in the basal and
suprabasal layers of the skin3 transforming the 7-dehi-
drocholesterol (provitamin D3) in previtamin D3 which is
then isomerised to vitamin D3. Vitamin D3 is inactive
form and needs to be activated through the hydroxy-
lation first in the liver at the C25 position, generating
25-hydroxyvitamin D3 (calcidiol, or 25(OH) D3). The sec-
ond hydroxylation occur in kidney at the C1 position pro-
ducing the active form, calcitriol (1a, 25-dihydroxyvitamin
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D3, or 1a, 25(OH)2D3). The hydroxylation in the kidney is
stimulated by parathyroid hormone (PTH) and suppre-
ssed by phosphate. The production of 1a, 25(OH)2D3 is
under tight feedback control, directly by serum calcium
and phosphate and indirectly by calcium through the de-
crease of PTH. In the circulation all forms of vitamin D
are biding to carrier proteins, mostly vitamin D-binding
protein (DBP) and albumin.
There are some evidence that keratinocytes also ex-
press a 1a-hydroxylase, and thus they are able to produce
substantial amount of 1a,25(OH)2D34. The cutaneous
production of calcitriol have an intracrine et autocrine
effects on keratinocytes and paracrine effects on sur-
rounding cells promoting cellular differentiation and apo-
ptosis4. Some new investigations have shown that skin
fibroblast also express the 25-hydroxylase thus produc-
ing 25OHD3. Lacking the expression of 1a-hydroxylase,
fibroblasts can not produce calcitriol but they may play
an important role in the supply of precursors (25OHD3)
for keratinocytes and circulating blood5.
Molecular mechanism of vitamin D
Vitamin D is a lipophilic molecule that easily passes
cellular membranes and binds to the nuclear VD recep-
tor (VDR). VDR is a member of a nuclear receptors super
family that consist of eight different receptors for steroid
hormones, receptor for vitamin D (VDR), receptors for
thyroid hormone and receptors for vitamin A-derivate
all-trans retinoic acid (T3R and RAR). Most of the action
of vitamin D is through the activation of VDR receptor in
nucleus making the complex heterodimer with the reti-
noid receptor leading to the transcription ant translation
of the genes forming various proteins – this is called
»genomic« action of vitamin D. The »nongenomic« action
is probably mediated through binding of vitamin D to the
membrane receptors initiating the cascade of reactions
which result in intracellular formation of second messen-
gers or phosphorylation of intercellular proteins – acti-
vating an intracellular enzyme or ion channel.
Classical Function of Vitamin D
The main function of vitamin D is to maintain serum
calcium levels in the normal range by increasing calcium
and phosphate absorption for the mineralisation of the
skeleton. In children vitamin D deficiency and consecu-
tive deficiency of calcium lead to impaired calcification of
the cartilage causing rickets. In adults the same scenario
lead to osteomalacia6 because newly formed bone matrix
(osteoid) is not well mineralised. Deficiency of vitamin D
also causes higher secretion of parathyroid hormone
(PTH) due to the low serum 1a,25(OH)2D3 and low se-
rum calcium resulting in high bone turnover and bone
resorption causing bone loss and contributing to osteopo-
rosis. Osteomalacia and osteoporosis increase the risk of
bone fracture especially hip fractures6.
Non-Classical Function of Vitamin D
Besides the classical target cells of Vitamin D such as
intestine, bone and kidney vitamin D receptor has been
demonstrated in most other tissues (hearth, skin, skeletal
muscle, prostate, uterus, melanocytes, colon, liver,...)7,8.
Also skin, prostate, colon, breast and many other tissues
express the enzyme to convert 25(OH)D to the active
form 1,25(OH)2 vitamin D regulating cell growth9. Skin
keratinocytes are the only cells in the body with the
whole pathway from 7-DHC to 1a,25(OH)2D3, so they are
both the site of calcitriol synthesis and target of this hor-
mone. The active hormone regulates proliferation (inhib-
iting proliferation in high doses, stimulating prolifera-
tion in low doses)10, differentiation and apoptosis of
keratinocytes and other cells. The positive action of vita-
min D analogues to skin diseases with impaired prolifer-
ation is due to its antiproliferative and prodiferrentiating
effects.
There is some evidence in the recent past that vita-
min D metabolites may protect against diabetes mellitus
type 1 down regulating dendritic and Th 1 cells, promo-
tion of Th2 lymphocytes, suppressing the antigen-pre-
senting capacity of macrophages11. Several ecological stu-
dies have shown a relationship between lower sunshine
exposure, higher latitude and vitamin D synthesis in skin
with the higher cancer prevalence or mortality for colon,
breast and prostate cancer12,13 as well as for malignant
lymphomas14. Deficiency of vitamin D plays a role in the
pathogenesis of some auto-immune disease. Lower risk
of multiple sclerosis is associated with the higher sun ex-
posure in the puberty15.
Factors that Influence Vitamin D Synthesis
Sun exposure
Sunlight is by far the best source of vitamin D for
most humans; therefore any limitation in sun exposure
may lead to vitamin D deficiency. The production of vita-
min D is dependent on UVB radiation which has great
seasonal and daily variations. The UVB insulation is
maximal around noon in the summer. During winter at
northern latitudes, the sunlight must pass longer dis-
tance trough the atmosphere absorbing the great propor-
tion of UVB light. UVB is also effectively absorbed by
glass and plastic16. Clothing and regular sunscreen use
prevent the photosynthesis of vitamin D. In darker skin
the capacity to produce the vitamin D is same as in light
skin but due to melanin absorption longer exposure of
UV-B is needed17.
Age
Vitamin D production capacity is diminished with age
due to a combination of skin getting thinner and a reduc-
tion in the concentration of vitamin D precursor 7-
dehidrocholesterol. It has been estimated that above the
age of 70, capacity to produce vitamin D is reduced to
one-third that of 20-years old1. Elderly people also tend
to spend most of the day inside; they protect their skin
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from the sun by wearing long sleeves and using regularly
sunscreens. Some investigators have found that intesti-
nal absorption of vitamin D is reduced by 40% in the el-
derly, whereas others have reported no reduction5.
Malabsorption results in malabsorption of fat soluble
vitamin D, but also in calcium leading to secondary
hyperparathyroidism and finally to increased 1,25(OH)
2D3 synthesis18. According to that the high risk popula-
tion of developing vitamin D3 deficiency are elderly peo-
ple, especially nursing-home residents, people with dark
skin living in the higher latitude, those who have darker
skin but cover most of the skin for religious reasons. Pa-
tients with skin type I, those who are under immuno-
suppressive therapy or have specific skin diseases (mela-
noma, Xeroderma pigmentosum) must be protected from
sun exposure.
Vitamin D Deficiency
Severe vitamin D deficiency is accompanied by num-
ber of nonspecific muscular and skeletal symptoms such
as bone and muscle pain, muscle weakness and cramps in
extremities, fatigue and paresthesia5. The most impor-
tant differential diagnoses are rheumatic diseases, poly-
myalgia rheumatica, and malignant disease. The prob-
lem is to determine what does vitamin D insufficiency
mean and still there is no consensus on the borderline
between vitamin D-deficient and vitamin D-sufficient
state. Nutritional status of vitamin D is measured by the
serum levels of 25(OH)D3 but the point is to determine
whether we should define vitamin D deficiency based on
population-based references limits for serum 25(OH)D3,
health-based limits for PTH levels, hypocalcaemia or ele-
vated alkaline phosphatase6 or as the deficiency at the
tissue level (bone and/or muscle diseases)5. Some authors
propose cut off at 20 ngl/mL of serum 25(OH)D3 to define
vitamin D deficiency6,19, concentration that have protec-
tion effects from secondary hyperparathyroidism but is
still consider by many authors to be too low. Published
lower reference values are in range of 40–50 nmol/L.
More recently according to defining vitamin D deficiency
based on data from various biomarkers (PTH, calcium
absorption) levels that are less of 32 ng/mL or 80 nmol/L
are considered as deficient20. It may be concluded that is
very difficult to delineate sharp diagnostic criteria for vi-
tamin D deficiency or insufficiency and that we need
careful studies to define optimal 25(OH)D3 concentra-
tion but it will certainly be higher than was previously
thought.
How much vitamin D do we really need?
The other issues is to determine how much vitamin D
must be ingested to reach the sufficient level of vitamin
D to protect us against cancer and other diseases in cases
when skin is not adequately exposed to UV radiation
(winter time at high latitude, elderly in-patients, people
with dark skin living in northern countries). The Recom-
mended Dietary Allowance (RDA) of vitamin D is deter-
mined as daily dietary intake sufficient to meet the re-
quirement of 98% of the individuals. The U.S. RDA from
1989 was 200 international units (IU)21, but recently ade-
quate intake in U.S. was defined to be 200 IU in adults
until age 50 yr, 400 IU in adults from 51 to 70 yr, and 600
IU in the elderly over 70 yr. In Europe the RDA for vita-
min D for adults from 18–64 yr as 0 to 400 IU and for el-
derly 65 yr and older is 400 IU22. The recent recommen-
dation for paediatrics population issued 2008 from Amer-
ican Academy of Paediatrician (AAP) is 400 IU for breast
feeding newborns until the consumption of 1000 ml of
fortified milk daily.
Conclusion
It is well known that UV radiation provokes not only
bio positive effects (e.g. production of vitamin D) but also
bionegativ effects (e.g. skin aging and photocarcinoge-
nesis). It is then essential to determine – how much UV
light do we need to achieve sufficient vitamin D level, so
we can take advantage of the beneficial effect of sunlight
while preventing the damaging consequences due to ex-
cessive exposure to sunlight. Exposure of the body to one
minimal erythemal dose (MED) of sunlight is equivalent
to ingesting about 10 000 IU of vitamin D321 therefore ex-
posure of less than 18% of the body surface (hands, arms
and face) to a 25%–50% of one MED in the spring, sum-
mer and autumn 2 to 3 times a week is adequate to sat-
isfy body requirement of vitamin D. We as health care
professionals have to recognised people at risk of devel-
oping vitamin D deficiency and monitor their vitamin D
status. Vitamin D deficiency has to be prevented and
treated by giving vitamin D orally21,23 in recommended
doses. Another option for treating vitamin D deficiency is
administration of a single dose of 50,000 IU vitamin D
once a week for 8 weeks or 50,000 IU once a month21,23.
We as dermatologists have to raise public awareness of
the potential health effects from excessive exposure to
UV radiation but also we have to be aware that adequate
blood level of vitamin D is necessary for optimal health.
There is no doubt that excessive sun exposure is muta-
genic and has to be avoided but very short and limited so-
lar exposure is at certain times of the year sufficient for
normal vitamin D synthesis. If anyone intending to stay
at the sun more then optimal duration for vitamin D syn-
thesis (it depends on latitude, season, skin type) use of
sunscreen with minimal sun protection factor (SPF) 15
as well as wearing of protective clothes and sunglasses
are essential. During the winter in most of the northern
countries and in risk population vitamin D supplemen-
tation is a good substitution for low sun exposure and
has to be recommended. In the future we need further
work to determine influence of low sun exposure and vi-
tamin D deficiency on occurrence of various cancers and
health problems, including malignant melanoma24.
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VITAMIN D – ISTINA I ZABLUDE
S A @ E T A K
Dobro je poznato da vitamin D ima pozitivan utjecaj na cjelokupno zdravlje ~ovjeka, ali noviji dokazi govore ne samo
o protektivnom utjecaju vitamina D na bolesti kostiju nego i za razli~ite karcinome (dojke, debelog crijeva, prostate),
multiplu sklerozu, hipertenziju i dijabetes tip 1. Osnovni izvor vitamina D za ~ovjeka je produkcija vitamina D3 u
keratinocitima pod utjecajem UVB zraka, ali novija istra`ivanja upu}uju da se aktivna forma vitamina D3 ne sintetizira
samo u stanicama bubrega ve} i u keratinocitima, stanicama prostate, debelog crijeva, dojke gdje ima autokrini u~inak
na navedene stanice te parakrini na okolne stanice. Zadnjih godina pove}ana incidencija karcinoma ko`e posebno mela-
noma i dokazanog utjecaja UV zraka u patogenezi istih, uvjetovala je sve sna`nije javnozdravstvene kampanje o za{titi
od sunca. Pitanje je koliku koli~inu UV zra~enja trebamo da bi odr`ali razinu izme|u negativnog i pozitivnog djelovanja
UV zra~enja. Mi kao dermatolozi moramo sudjelovati u edukativnim i javnozdravstvenim kampanjama za za{titu od
pretjeranog izlaganja suncu, ali moramo biti svjesni da je adekvatna koli~ina vitamin D neophodna za optimalno
zdravlje. Kao preporuka u budu}nosti sve javnozdrastvene kampanje moraju uzeti u obzir ne samo {tetno djelovanje
UV zraka ve} i njegov pozitivan efekt, kao i promovirati oralnu nadoknadu vitamina D posebno u zimskim mjesecima i
kod rizi~ne populacije.
S. Poduje et al.: Vitamin D, Coll. Antropol. 32 (2008) Suppl. 2: 159–162
162
